Notably, patients with highly hERG1-expressing glioblastoma but not those with low expression showed in univariate analysis a benefit in terms of overall survival from “non-torsadogenic” hERG1-inhibiting drugs (Pointer et al., 2017). The gene discussed is KCNH2; the disease is glioblastoma.